in early academic research that led to the development of Spinraza , said more important than the list price of the drug is whether patients who need it will get it ."Are our families going to get access to the drug the list price of the drug the end the list price of the drug " he said .About 1 in 10 , 000 the drug born with spinal muscular atrophy   —    or about 400 a year in the United States   —    and it is among the leading genetic causes of death in infants .